Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.45 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.36 |
| ▸ | SYK | P43405 | 6/20 | 0.36 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 3/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482851 | 0.96 | TOP1 (0.48) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL6475561 | 0.93 | TOP1 (0.51) | TOP1FERMT2KAT2BCSNK2A2CSNK2A1 | |
| SCHEMBL6483946 | 0.92 | TOP1 (0.50) | TOP1FERMT2KAT2BCSNK2A2CSNK2A1 | |
| SCHEMBL6475257 | 0.92 | TOP1 (0.49) | TOP1CSNK2A2CSNK2A1CSNK2BTERT | |
| SCHEMBL5778588 | 0.88 | TOP1 (0.58) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL5781260 | 0.87 | TOP1 (0.52) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL6475949 | 0.86 | TOP1 (0.47) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL5784467 | 0.84 | TOP1 (0.47) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL5780915 | 0.84 | TOP1 (0.58) | TOP1KAT2BCSNK2A2CSNK2A1CSNK2B | |
| SCHEMBL6482651 | 0.83 | TOP1 (0.50) | TOP1FERMT2CSNK2A2CSNK2A1CSNK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946472-B2 | Polycyclic compounds exhibiting anti-tumor activities | HOFFMAN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093265-A1 | DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | TOP1 74/4885FERMT2 4290/4885KAT2B 1516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.